Vicore Pharma Holding AB
VCRE | NASDAQ
$9.89
+$0.09 (+0.92%)
Nov 2, 2026, 12:37 PM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 |
|---|---|---|---|---|
Cash & Equivalents | 44.2M | 377.42M | 578.15M | 49.93M |
Short-Term Investments | 49.2M | 682.37M | 588.59M | 38.85M |
Long-Term Investments | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 388.73K | 3.02M | 1.71M | 149.66K |
Receivables | n/a | n/a | n/a | n/a |
Inventory | n/a | n/a | n/a | n/a |
Other Current Assets | 767.97K | 14.46M | 16.24M | 651.86K |
Total Current Assets | 95.52M | 1.07B | 1.22B | 91.91M |
Property-Plant & Equipment | n/a | n/a | n/a | n/a |
Goodwill & Intangibles | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 388.73K | 3.02M | 1.71M | 149.66K |
Total Assets | 95.91M | 1.08B | 1.22B | 92.06M |
Account Payables | 2.06M | 34.1M | 39.47M | 1.57M |
Deferred Revenue | n/a | n/a | n/a | n/a |
Short-Term Debt | n/a | n/a | n/a | n/a |
Other Current Liabilities | 368.41K | 50.57M | 78.9M | 727.59K |
Total Current Liabilities | 7.53M | 84.66M | 118.43M | 6.63M |
Long-Term Debt | n/a | n/a | n/a | n/a |
Other Long-Term Liabilities | 330.36K | 1.69M | 4.45M | 599.6K |
Total Long-Term Liabilities | 330.36K | 1.69M | 4.74M | 599.6K |
Total Liabilities | 7.86M | 86.35M | 123.18M | 7.23M |
Total Debt | n/a | n/a | n/a | n/a |
Book Value | 88.04M | 990.91M | 1.1B | 84.83M |
Book Value Per Share | 0.31 | 35.20 | 42.83 | 0.36 |
Common Stock | 88.04M | n/a | 140.76M | 12.46M |
Retained Earnings | n/a | n/a | -1.92B | n/a |
Comprehensive Income | n/a | n/a | n/a | 72.37M |
Shareholders Equity | 88.04M | 990.91M | 1.1B | 84.83M |
Total Investments | 49.2M | 682.37M | 588.59M | 38.85M |
Add to Watchlist
Select watchlists to add or remove VCRE